FDA Approves CAR T-Cell Therapy for MCL

(MedPage Today) -- WASHINGTON--The FDA on Friday approved the first chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory mantle cell lymphoma (MCL).
Brexucabtagene autoleucel (Tecartus) consists of a patient's own T cells...